NO20074311L - Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet - Google Patents
Kinazolinderivat med tyrosinkinase-inhiberendeaktivitetInfo
- Publication number
- NO20074311L NO20074311L NO20074311A NO20074311A NO20074311L NO 20074311 L NO20074311 L NO 20074311L NO 20074311 A NO20074311 A NO 20074311A NO 20074311 A NO20074311 A NO 20074311A NO 20074311 L NO20074311 L NO 20074311L
- Authority
- NO
- Norway
- Prior art keywords
- substituted
- alkyl group
- hydrogen atom
- tyrosine kinase
- inhibitory activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En forbindelse representert ved den generelle formel (I) eller et farmasøytisk aksepterbart salt derav eller et solvat av forbindelsen eller saltet: (I) hvor Rx representerer en gruppe representert ved formel (II): hvor representerer et hydrogenatom, en alkylgmppe som kan være substituert eller lignende,. Z representerer -O-, -N(R)- eller lignende, Rrepresenterer et hydrogenatom, en alkylgruppe eller lignende, Rrepresenterer et hydrogenatom, en alkylgruppe som kan være substituert eller lignende, R representerer et hydrogenatom, en alkylgruppe som kan være substituert eller lignende, Rrepresenterer en alkylgruppe som kan være substituert eller lignende, Wrepresenterer en ikke-aromatisk nitrogenert heterocyklisk gruppe som kan være substituert, og Rrepresenterer et hydrogenatom, en alkylgruppe som kan være substituert eller lignende; Rog Rrepresenterer uavhengig et hydrogenatom, en alkylgruppe som kan være substituert eller lignende; X representerer -O-, -S-, -N(R)- eller lignende; R representerer et hydrogenatom, en alkylgruppe eller lignende; og A representerer en fenylgruppe som kan være substituert eller lignende. Forbindelsen kan inhibere både EGF reseptor-tyrosinkinase og HER2 tyrosinkinase.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005047383 | 2005-02-23 | ||
JP2005156828 | 2005-05-30 | ||
PCT/JP2006/303125 WO2006090717A1 (ja) | 2005-02-23 | 2006-02-22 | チロシンキナーゼ阻害作用を有するキナゾリン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20074311L true NO20074311L (no) | 2007-11-23 |
NO343403B1 NO343403B1 (no) | 2019-02-25 |
Family
ID=36927355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074311A NO343403B1 (no) | 2005-02-23 | 2007-08-23 | Kinazolinderivat med tyrosinkinase-inhiberende aktivitet og farmasøytisk sammensetning |
Country Status (16)
Country | Link |
---|---|
US (2) | US8202879B2 (no) |
EP (1) | EP1854789B1 (no) |
JP (1) | JP4137174B2 (no) |
KR (1) | KR100910333B1 (no) |
CN (1) | CN101163684B (no) |
AU (1) | AU2006216266C1 (no) |
BR (1) | BRPI0606905B1 (no) |
CA (1) | CA2599328C (no) |
DK (1) | DK1854789T3 (no) |
ES (1) | ES2431843T3 (no) |
NO (1) | NO343403B1 (no) |
PL (1) | PL1854789T3 (no) |
PT (1) | PT1854789E (no) |
RU (1) | RU2414457C2 (no) |
TW (1) | TWI372147B (no) |
WO (1) | WO2006090717A1 (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1854789T3 (da) * | 2005-02-23 | 2013-10-21 | Shionogi & Co | Quinazolinderivat med tyrosin-kinase inhibitorisk aktivitet |
CN101003514A (zh) * | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
SG174774A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Quinazoline based egfr inhibitors containing a zinc binding moiety |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
MX353900B (es) | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
TWI466872B (zh) | 2008-12-25 | 2015-01-01 | Shionogi & Co | 喹唑啉衍生物之製造方法 |
PE20150041A1 (es) | 2011-10-27 | 2015-01-28 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
CN103288756B (zh) * | 2012-02-29 | 2016-04-20 | 江苏先声药物研究有限公司 | 一种喹唑啉中间体的甲醇溶剂合物及其制备方法 |
JP6464139B2 (ja) | 2013-03-14 | 2019-02-06 | コンバージーン・リミテッド・ライアビリティ・カンパニーConvergene Llc | ブロモドメイン含有タンパク質の阻害のための方法および組成物 |
JP6099182B2 (ja) * | 2014-05-29 | 2017-03-22 | 塩野義製薬株式会社 | アルキニルケトン誘導体の製造方法 |
PL3330267T3 (pl) | 2015-07-29 | 2022-04-04 | Shionogi&Co., Ltd. | Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu |
MX2018004109A (es) | 2015-10-05 | 2018-09-27 | Univ Columbia | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. |
CN109641886B (zh) | 2015-11-25 | 2022-11-18 | 康威基内有限公司 | 双环bet布罗莫结构域抑制剂及其用途 |
US20180030403A1 (en) | 2016-07-28 | 2018-02-01 | Bobban Subhadra | Devices, systems and methods for the production of humanized gut commensal microbiota |
CN110430881A (zh) * | 2017-01-30 | 2019-11-08 | 盐野义制药株式会社 | 含有喹唑啉衍生物的固体制剂 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
EP0817775B1 (en) * | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
ID19609A (id) * | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
AU763242B2 (en) | 1999-09-21 | 2003-07-17 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
CA2442742A1 (en) * | 2001-02-21 | 2002-08-29 | Mitsubishi Pharma Corporation | Quinazoline derivatives |
WO2003031406A2 (en) | 2001-10-12 | 2003-04-17 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
AP2005003260A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel triazole compounds as transforming growth factor (TGF) inhibitors. |
WO2004069145A2 (en) | 2003-02-07 | 2004-08-19 | Dr. Reddy's Laboratories Ltd. | Anticancer compounds, process for their preparation and pharmaceutical compositions containing them |
JO2785B1 (en) | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
US20100190150A1 (en) | 2004-01-07 | 2010-07-29 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
WO2005070020A2 (en) | 2004-01-23 | 2005-08-04 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
DK1854789T3 (da) * | 2005-02-23 | 2013-10-21 | Shionogi & Co | Quinazolinderivat med tyrosin-kinase inhibitorisk aktivitet |
-
2006
- 2006-02-22 DK DK06714265.3T patent/DK1854789T3/da active
- 2006-02-22 KR KR1020077019256A patent/KR100910333B1/ko active IP Right Grant
- 2006-02-22 BR BRPI0606905-3A patent/BRPI0606905B1/pt active IP Right Grant
- 2006-02-22 RU RU2007135023/04A patent/RU2414457C2/ru active
- 2006-02-22 WO PCT/JP2006/303125 patent/WO2006090717A1/ja active Application Filing
- 2006-02-22 PL PL06714265T patent/PL1854789T3/pl unknown
- 2006-02-22 ES ES06714265T patent/ES2431843T3/es active Active
- 2006-02-22 AU AU2006216266A patent/AU2006216266C1/en active Active
- 2006-02-22 PT PT67142653T patent/PT1854789E/pt unknown
- 2006-02-22 EP EP06714265.3A patent/EP1854789B1/en active Active
- 2006-02-22 JP JP2007504734A patent/JP4137174B2/ja active Active
- 2006-02-22 US US11/884,819 patent/US8202879B2/en active Active
- 2006-02-22 CA CA2599328A patent/CA2599328C/en active Active
- 2006-02-22 CN CN2006800136753A patent/CN101163684B/zh active Active
- 2006-02-23 TW TW095106013A patent/TWI372147B/zh active
-
2007
- 2007-08-23 NO NO20074311A patent/NO343403B1/no unknown
-
2012
- 2012-01-26 US US13/359,326 patent/US8349857B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1854789B1 (en) | 2013-10-09 |
TWI372147B (en) | 2012-09-11 |
KR100910333B1 (ko) | 2009-07-31 |
PL1854789T3 (pl) | 2014-03-31 |
EP1854789A4 (en) | 2009-06-17 |
US20090143414A1 (en) | 2009-06-04 |
DK1854789T3 (da) | 2013-10-21 |
US8202879B2 (en) | 2012-06-19 |
BRPI0606905A2 (pt) | 2009-07-28 |
CN101163684A (zh) | 2008-04-16 |
BRPI0606905B1 (pt) | 2021-06-01 |
RU2414457C2 (ru) | 2011-03-20 |
KR20070098941A (ko) | 2007-10-05 |
US20120123114A1 (en) | 2012-05-17 |
CN101163684B (zh) | 2012-08-29 |
CA2599328C (en) | 2012-04-17 |
EP1854789A1 (en) | 2007-11-14 |
JP4137174B2 (ja) | 2008-08-20 |
ES2431843T3 (es) | 2013-11-28 |
AU2006216266A1 (en) | 2006-08-31 |
AU2006216266A2 (en) | 2006-08-31 |
CA2599328A1 (en) | 2006-08-31 |
AU2006216266C1 (en) | 2010-08-26 |
AU2006216266A8 (en) | 2009-04-02 |
JPWO2006090717A1 (ja) | 2008-07-24 |
US8349857B2 (en) | 2013-01-08 |
NO343403B1 (no) | 2019-02-25 |
PT1854789E (pt) | 2013-10-23 |
RU2007135023A (ru) | 2009-03-27 |
AU2006216266B2 (en) | 2010-02-18 |
TW200640880A (en) | 2006-12-01 |
WO2006090717A1 (ja) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20074311L (no) | Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet | |
WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
NO20073956L (no) | Pyrazolderivater for inhibering av CDK og GSK | |
WO2005074603A3 (en) | Aminobenzoxazoles as therapeutic agents | |
NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
TW200618800A (en) | Heterocyclic compounds | |
EA200801381A1 (ru) | Производные пиримидина | |
TN2010000052A1 (fr) | Derives de pyrazole et leur utilisation comme inhibiteurs de raf | |
WO2007016392A3 (en) | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | |
NO20063501L (no) | Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20082482L (no) | Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer | |
NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
NO20070532L (no) | Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer | |
NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
TNSN08089A1 (en) | Substituted benzimidazoles and methods of preparation | |
ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
NO20083923L (no) | Pyrazolkinoloner er potente parp-inhibitorer | |
NO20062185L (no) | Hepatitt C virus-inhibitorer | |
WO2008060476A3 (en) | Nitrogen-containing heterocyclic compounds and methods of use thereof | |
NO20084583L (no) | Makrosykliske kinase-inhibitorer | |
TW200637539A (en) | CTGF inhibitors | |
NO20063647L (no) | Nye inhibitorer av chymase | |
NO20065327L (no) | Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid. | |
WO2009069736A1 (ja) | 含窒素化合物 |